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Serum responses against Mycobacterium tuberculosis HSP16 were determined for children with tuberculosis
(TB) and for healthy purified protein derivative (PPD)-positive and PPD-negative children. Immunoglobulin
G (IgG) and IgM responses were higher for TB patients than for other groups. After chemotherapy, IgM and
IgG responses decreased for TB patients and PPD-positive subjects. Monitoring of anti-M. tuberculosis HSP16
responses could assist in the management of pediatric TB.
Tuberculosis (TB), caused by Mycobacterium tuberculosis,
is one of the most relevant worldwide health problems,
resulting in at least 1.5 million deaths each year (10, 11).
Although pediatric cases represent a small percentage of all
TB cases, infected children are a source of transmission of
mycobacteria to adults (4, 5). In recent years, researchers’
attempts have been directed toward the characterization of
mycobacterial antigens that interact with the host humoral
immune system (3, 6, 9). However, knowledge about hu-
moral immune responses in children with TB is limited, and
therefore, we investigated serum immunoglobulin G (IgG)
and IgM responses to M. tuberculosis HSP16, a protein that
is part of the latency operon (DosR) and is associated with
dormant bacilli (7, 13).
Children who had not been vaccinated with Mycobacte-
rium bovis BCG and who were from the same geographical
area of Sicily and from similar socioeconomic backgrounds
were recruited. Diagnosis of TB was established by the pres-
ence of clinical symptoms of TB, by chest radiography, by a
positive result on the tuberculin (purified protein derivative
[PPD]) skin test, and by symptomatic improvement after
chemotherapy. All TB patients (n  45; age range, 1 to 13
years; average age  standard deviation [SD], 5.61  3.24
years) included in this study had positive PPD skin tests. TB
patients were treated with a commonly used mixture of
antitubercular drugs containing isoniazid, rifampin, and
pyrazinamide. Healthy children included in this study were
not household contacts of known TB cases and were divided
into two groups: PPD reactive (PPD) (n  60; age range,
1 to 14 years; average age  SD, 7.1  4.1 years) and
non-PPD reactive (PPD) (n  17; age range, 3 to 14 years;
average age  SD, 7.2  3.5 years). PPD subjects were
treated with isoniazid only and followed the same schedule
used for TB patients.
Enzyme-linked immunosorbent assay plates (MaxiSorp;
Nunc, Copenhagen, Denmark) were coated overnight at
37°C with 50 l/well of 1-g/ml recombinant HSP16 (a gift
from J. Ivanyi) in carbonate buffer (0.1 M sodium bicarbon-
ate in distilled water [pH 8.2]). Plates were blocked with
phosphate-buffered saline (PBS)–10% fetal calf serum for
1 h at 37°C. Plates were incubated for 90 min at 37°C with
50 l of serum samples diluted 1:50 in PBS. After four
washes with PBS-Tween, 50 l of anti-human IgG or IgM
(both peroxidase conjugated; Sigma-Aldrich, Milan, Italy)
was added to each well, and the mixture was incubated for
2 h at 37°C. The plates were washed six times with PBS-
Tween and then colorimetrically developed with o-phenyl-
enediamine (Sigma-Aldrich) in 0.1 M citrate phosphate
buffer in the presence of H2O2. Plates were read as the
optical density at 492 nm (OD492) with an enzyme-linked
immunosorbent assay multiwell reader (Sigma-Aldrich). Af-
ter subtraction of background values, represented by the
OD detected in wells without antigen, samples showing an
OD of 0.150 were considered positive. Differences among
group means were evaluated by the Mann-Whitney test. P
values of 0.05 were considered significant.
To assess whether determination of HSP16-specific anti-
body responses could be useful for monitoring the efficacy of
chemotherapy, we measured HSP16-specific IgG and IgM
levels in sera from patients and healthy controls (PPD)
before and after therapy. The results are presented as per-
centages of anti-HSP16 IgG- and IgM-positive sera (Fig. 1)
and as mean ODs before and after chemotherapy (Fig. 2).
The percentages of HSP16-specific IgG and IgM responders
decreased after chemotherapy both for TB patients (from
73.3 to 37.7% for IgG; from 73.3 to 20% for IgM) and for
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healthy PPD subjects (from 48.3 to 25% for IgG; from
58.33 to 15% for IgM) (Fig. 1A and B, respectively). Per-
centages of sera positive for HSP16-specific IgG or IgM
were low for PPD patients (Fig. 1C).
Further, anti-M. tuberculosis HSP16 IgG (Fig. 2A and B)
and IgM (Fig. 2C and D) levels of TB patients and PPD
subjects were compared before and after therapy. Before
therapy, mean responses were higher for TB patients (ODs,
0.330  0.231 for IgG and 0.390  0.266 for IgM) than for
healthy PPD (ODs, 0.167  0.147 for IgG and 0.237 
0.213 for IgM) or PPD (ODs, 0.109  0.135 for IgG and
0.104  0.162 for IgM) subjects. After chemotherapy, IgG
and IgM levels decreased more in TB patients (ODs, 0.190 
0.174 and 0.120  0.085, respectively) than in healthy PPD
individuals (ODs, 0.113  0.078 and 0.094  0.067, respectively)
(P  0.05 for all parameters).
We found that levels of IgG and IgM against the 16-kDa
antigen in infected children and in healthy contacts decrease
after therapy. The recognition of the 16-kDa antigen is
probably due to M. tuberculosis infection, since it has been
observed mainly for patients, as confirmed by a study of
adults (12). This observation could be interpreted as due to
activation of memory B-cell clones against environmental
mycobacteria in patients but not in adult contacts exposed to
previous therapy. Naı¨ve B-cell clones in children exposed to
mycobacteria could induce the secretion of antibodies also
in healthy contacts not previously treated with drugs. The
response to the 16-kDa antigen could be associated with
ESAT-6; in fact, antibodies against HSP16 and ESAT-6
could be detected during tubercular infection (1). The fall in
16-kDa-antigen responses after therapy has also been doc-
umented for adults (2). It has been reported that anti-16-
kDa antibody levels in children could be elevated in re-
sponse to infections, even without clinically apparent TB
(8). These data are in agreement with our findings that IgG
and IgM against the 16-kDa antigen were also detected in
healthy PPD subjects. In particular, the novelty of our
finding lies in the decrease in the level of the IgM response
in healthy PPD children after prophylaxis. These data con-
firm that healthy contacts recognize the 16-kDa protein, as
previously reported (2), and also that IgM could be useful
for detecting the efficacy of antitubercular prophylaxis. The
decrease in anti-16-kDa-antigen IgM levels after therapy in
healthy PPD contacts could be due to the inefficacy of
therapy rather than a primary antibody response against a
marker of latent infection. Our interpretation of these data
could mean that after therapy, there is a percentage of
children who still remain susceptible to mycobacterial infec-
tion. On the other hand, the persistence of IgG against the
16-kDa antigen could be a marker of serological memory
that could protect individuals against reinfection.
In conclusion, the dynamics of anti-HSP16 IgG and IgM
responses in children during chemotherapy could be used
alongside other diagnostic and clinical criteria to monitor
FIG. 1. Frequencies of anti-HSP16 IgG or IgM responses before and after chemotherapy. Shown are percentages of sera with IgG and IgM
responses to HSP16 for TB patients (n  45) (A) and for healthy PPD (n  60) (B) and PPD (n  17) (C) subjects. Frequencies of positive
sera were obtained by dividing the number of positive sera for each group by the total number of sera tested for that group. Hatched bars, results
obtained with sera after 4 months of therapy.
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the efficacy of antitubercular drugs, not only for TB patients
but also for healthy contacts, who are a potential reservoir
for the dissemination of tubercle bacilli.
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